Market Overview

UPDATE: Goldman Sachs Upgrades Amgen to CL-Buy on Favorable Catalysts, Upside Potential

Share:
Related AMGN
Barron's Picks And Pans: Best Dividend Stocks, Symantec, GoldCorp And More
What Tidings From the Tetons? Long-Awaited Yellen Speech Today
Amgen's osteoporosis med Prolia shows treatment benefit in patients receiving glucocorticoid therapy (Seeking Alpha)

In a report published Wednesday, Goldman Sachs analyst Terence Flynn upgraded the rating on Amgen (NASDAQ: AMGN) from Neutral to Conviction List Buy, and raised the price target from $100.00 to $130.00.

In the report, Flynn noted, “We switch to AMGN from BIIB, as we see a more favorable combination of catalysts and upside potential. AMGN is entering a period where several of its key biologic franchises are coming off patent between 4Q13 and 2H15. However, we believe this is anticipated by investors and for the most part already reflected in consensus estimates. We project that AMGN's pipeline (key readouts in 1Q14-2015) and own biosimilars (first launch in 2017) will allow it to replace the potential revenue that could be lost to competition and grow its base.”

Amgen closed on Tuesday at $104.21.

Latest Ratings for AMGN

DateFirmActionFromTo
Aug 2016Gabelli & Co.Initiates Coverage onHold
Jul 2016CitigroupMaintainsNeutral
Jul 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!